Fecal Microbiota Transplantation for the Prevention of Infectious Complications After Liver Transplantation
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 14, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called fecal microbiota transplantation (FMT) to help prevent infections in patients who are undergoing liver transplantation. Liver transplant patients often face a high risk of serious infections caused by multi-drug resistant bacteria, especially because they frequently receive strong antibiotics after their surgery. The researchers believe that using FMT may help reduce these infections by restoring a healthier balance of bacteria in the gut and removing harmful bacteria.
To participate in this study, you need to be an adult (18 years or older) who is waiting for a liver transplant. You must also agree to take part in the research. However, there are some important reasons you might not be eligible, such as having had certain surgeries, being pregnant or breastfeeding, or having specific health conditions. If you decide to join, you can expect to receive the FMT treatment and be monitored for any changes in your health, particularly regarding infection rates. This trial is currently recruiting participants, and it aims to find effective ways to improve outcomes for liver transplant patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (age≥18 years) patients listed for OLT for various etiologies.
- • Patient's consent to participate in the study
- Exclusion Criteria:
- • Previous total colectomy
- • Pregnancy or breastfeeding
- • Patients on oral or intravenous antimicrobial agents
- • HIV positive and not well controlled on antiretroviral therapy, or CD4+ \<200/ mm3
- • Active SARS-CoV-2 infection
- • Neutropenia \<0.5X10\^9/L
- • Toxic megacolon
- • Contraindications to colonoscopy
- • Any conditions for which, according to the physician, FMT endangers the patient's health
- • History of hypersensitivity to macrogol contained in bowel preparations.
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Giovanni Barbara, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported